Zacks Investment Research upgraded shares of Pharma Mar (NASDAQ:PHMMF) from a hold rating to a buy rating in a research note released on Tuesday, September 12th. The firm currently has $5.00 price target on the stock.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Pharma Mar (PHMMF) traded down 0.77% during midday trading on Tuesday, hitting $3.85. 250 shares of the company traded hands. Pharma Mar has a 12-month low of $2.40 and a 12-month high of $4.80. The company’s market capitalization is $955.19 million. The stock’s 50-day moving average price is $4.42 and its 200 day moving average price is $4.09.
TRADEMARK VIOLATION NOTICE: “Pharma Mar (NASDAQ:PHMMF) Upgraded by Zacks Investment Research to Buy” was published by BBNS and is owned by of BBNS. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://baseballnewssource.com/markets/pharma-mar-phmmf-rating-increased-to-buy-at-zacks-investment-research/1639287.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with our FREE daily email newsletter.